Get the Stockscreener App
24.18
3.20%
-0.80
Pre-market:
24.20
0.02
+0.08%
Uniqure N V stock is traded at $24.18, with a volume of 1.33M.
It is down -3.20% in the last 24 hours and down -13.05% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
See More
Previous Close:
$24.98
Open:
$24.76
24h Volume:
1.33M
Relative Volume:
0.28
Market Cap:
$1.51B
Revenue:
$14.34M
Net Income/Loss:
$-199.00M
P/E Ratio:
-6.1684
EPS:
-3.92
Net Cash Flow:
$-183.51M
1W Performance:
+10.46%
1M Performance:
-13.05%
6M Performance:
+73.33%
1Y Performance:
+38.73%
1-Day Range:
$23.74
$24.87
1-Week Range:
$22.76
$25.75
52-Week Range:
$7.76
$71.50
Uniqure N V Stock (QURE) Company Profile
Name
Uniqure N V
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
24.18 | 1.56B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.21 | 116.79B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.17 | 81.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.70 | 53.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
845.95 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.77 | 37.48B | 447.02M | -1.18B | -906.14M | -6.1812 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-14-25 | Upgrade | Mizuho | Neutral → Outperform |
| Apr-01-25 | Resumed | Chardan Capital Markets | Buy |
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure N V Stock (QURE) Latest News
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - PR Newswire
uniQure (NASDAQ:QURE) Trading Down 4.6%Here's Why - MarketBeat
Cell And Gene Therapy Leaders See Transformative Results Outweighing Industry Setbacks - Citeline News & Insights
What Do Analysts Think About UniQure (QURE)? - Finviz
How uniQure N.V. stock benefits from tech adoptionJuly 2025 Closing Moves & Fast Moving Stock Watchlists - Улправда
Quarterly Earnings: How uniQure N.V. stock benefits from tech adoptionJuly 2025 Setups & Reliable Breakout Forecasts - Улправда
Is uniQure N.V. stock positioned for long term growthLong Setup & Growth-Oriented Investment Plans - ulpravda.ru
What hedge fund moves indicate for uniQure N.V. (UQ1) stockJuly 2025 Breakouts & AI Powered Buy/Sell Recommendations - Улправда
How sustainable is uniQure N.V. stock dividend payoutJuly 2025 Trends & Weekly Watchlist for Consistent Profits - ulpravda.ru
uniQure: Why Waiting For Clarity Beats Chasing The Next Step Jump (NASDAQ:QURE) - Seeking Alpha
uniQure (NASDAQ:QURE) Shares Up 14%What's Next? - MarketBeat
Sanders Morris Harris LLC Makes New $5.08 Million Investment in uniQure N.V. $QURE - MarketBeat
Revenue per share of uniQure N.V. – LSX:A1XDTV - TradingView — Track All Markets
QURE Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - PR Newswire
What's Going On With uniQure Stock On Tuesday? - Benzinga
uniQure (NASDAQ:QURE) Shares Gap UpWhat's Next? - MarketBeat
uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead - ts2.tech
UniQure (QURE) Stock Drop Looms as FDA Concern Over Huntington's Data Spurs Mizuho Downgrade and Delayed Launch - Finviz
UniQure (QURE) Stock Drop Looms as FDA Concern Over Huntington’s Data Spurs Mizuho Downgrade and Delayed Launch - Insider Monkey
(QURE) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Wall Street Has a Positive Outlook on uniQure N.V. (QURE) Despite Challenges From The FDA - MSN
QURE INVESTIGATION: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
Stifel Maintains uniQure N.V. (QURE) Buy Recommendation - Nasdaq
QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
uniQure (NASDAQ:QURE) Price Target Lowered to $40.00 at Stifel Nicolaus - MarketBeat
Roku To Rally More Than 28%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
uniQure (QURE) Price Target Lowered by Stifel Analyst | QURE Sto - GuruFocus
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - Prime Publishers, Inc.
Stempoint Capital LP Has $7.98 Million Stock Holdings in uniQure N.V. $QURE - MarketBeat
Mizuho Maintains uniQure N.V. (QURE) Outperform Recommendation - Nasdaq
Mizuho Lowers Price Target for uniQure (QURE) to $33.00 | QURE S - GuruFocus
Mizuho Securities Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $33 - 富途牛牛
Swiss National Bank Makes New Investment in uniQure N.V. $QURE - MarketBeat
Mizuho Securities Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $33 - 富途牛牛
uniQure NV (HAM:UQ1) Non Operating Income : €-3.54 Mil (TTM As of Sep. 2025) - GuruFocus
uniQure NV (HAM:UQ1) Asset Impairment Charge : €0.00 Mil (TTM As of Sep. 2025) - GuruFocus
uniQure NV (HAM:UQ1) Total Long-Term Liabilities : €476.27 Mil (As of Sep. 2025) - GuruFocus
Notice of Investigation of QURE: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - GlobeNewswire Inc.
Voss Capital LP Takes $1.74 Million Position in uniQure N.V. $QURE - MarketBeat
Pale Fire Capital SE Boosts Stake in uniQure N.V. $QURE - MarketBeat
Progress on AMT-130 Halts uniQure N.V.’s (QURE) Downtrend - Insider Monkey
uniQure (NASDAQ:QURE) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
7 Hidden Multibagger Stocks to Invest In - Insider Monkey
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years – Company AnnouncementFT.com - Financial Times
UniQure stock falls after FDA's notes on pre-application of AMT-130 - MSN
Aug Wrap: Can uniQure NV stock surprise with earnings upside2025 Key Highlights & Smart Swing Trading Techniques - BỘ NỘI VỤ
uniQure (NASDAQ:QURE) Shares Down 5.1%Here's What Happened - MarketBeat
QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - Your Wyoming Link
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
uniQure (NASDAQ:QURE) Receives "Buy" Rating from Chardan Capital - MarketBeat
Uniqure N V Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):